Don't Expect the New Anticoagulant Betrixaban to be Added to Your Formulary

You'll hear buzz about betrixaban (Bevyxxa, beh-VYKE-sah), a new direct oral anticoagulant (DOAC) for extended VTE prophylaxis.

We know extending VTE prophylaxis after discharge is helpful for certain high-risk surgical patients...such as after hip or knee surgery. But the bleeding risk outweighs the benefit in most other patients.

Now betrixaban will be promoted for VTE prophylaxis in MEDICAL inpatients...and after discharge for up to 6 weeks total duration.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals